Effectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection Rate
Primary Purpose
Cholecystitis
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Cefotetan
Sponsored by
About this trial
This is an interventional prevention trial for Cholecystitis focused on measuring GB stone
Eligibility Criteria
Inclusion Criteria:
patients who have diagnosed -cholecystitis with / without GB stone, GB polyp
Exclusion Criteria:
- Suspected cholangitis and GB cancer
- CBD stone history
- Preoperative administration of antibiotics within 7days.
- Suspected pregnancy
- Open conversion.
- Patients refuse this study
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Antibiotic treatment group
Non-antibiotic treatment group
Arm Description
They were Antibiotic treatment group (AG, cefotetan 1g, 1 dose/prophylactic) before surgery.
They were Non-antibiotics treatment such as cefotetan 1g before surgery.
Outcomes
Primary Outcome Measures
surgical complication
surgical site infection
Secondary Outcome Measures
Full Information
NCT ID
NCT04726046
First Posted
September 18, 2017
Last Updated
January 25, 2021
Sponsor
Chonbuk National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04726046
Brief Title
Effectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection Rate
Official Title
Prospective Randomized Control Study of Clinical Effectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection Rate
Study Type
Interventional
2. Study Status
Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
April 1, 2014 (Actual)
Primary Completion Date
August 1, 2015 (Actual)
Study Completion Date
September 25, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chonbuk National University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
529 patients performed elective LCC at Chonbuk National University Hospital between April 2014 and August 2015. Total 509 patients were enrolled by inclusion criteria.
They were randomized studied by comparing with antibiotic group (n=249, AG, cefotetan 1g, 1 dose/prophylactic) and non-antibiotic group (n=260, NAG) by table of random numbers. The clinical variables were pre and post-operatively blood tests enclude WBC, ESR, CRP, body temperatures, symptoms and imaging of chest x-ray to evaluate the infections.
Detailed Description
529 patients performed elective LCC at Chonbuk National University Hospital between April 2014 and August 2015. Total 509 patients were enrolled by inclusion criteria. They were randomized studied by comparing with antibiotic group (n=249, AG, cefotetan 1g, 1 dose/prophylactic) and non-antibiotic group (n=260, NAG) by table of random numbers. The clinical variables were pre and post-operatively blood tests enclude WBC, ESR, CRP, body temperatures, symptoms and imaging of chest x-ray to evaluate the infections.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cholecystitis
Keywords
GB stone
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
529 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Antibiotic treatment group
Arm Type
Experimental
Arm Description
They were Antibiotic treatment group (AG, cefotetan 1g, 1 dose/prophylactic) before surgery.
Arm Title
Non-antibiotic treatment group
Arm Type
No Intervention
Arm Description
They were Non-antibiotics treatment such as cefotetan 1g before surgery.
Intervention Type
Drug
Intervention Name(s)
Cefotetan
Other Intervention Name(s)
antibiotics group
Intervention Description
Cefotetan (as Disodium) 1 GM Injection before surgery
Primary Outcome Measure Information:
Title
surgical complication
Description
surgical site infection
Time Frame
30days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients who have diagnosed -cholecystitis with / without GB stone, GB polyp
Exclusion Criteria:
Suspected cholangitis and GB cancer
CBD stone history
Preoperative administration of antibiotics within 7days.
Suspected pregnancy
Open conversion.
Patients refuse this study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jae Do Yang
Organizational Affiliation
Chonkbuk national university
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection Rate
We'll reach out to this number within 24 hrs